RDY vs NBIX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RDY · Dr. Reddy's Laboratories$14.89 ▲ 0.40%
NBIX · Neurocrine Biosciences$150.57 ▼ 3.84%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RDY +9.8%
- NBIX +6.6%
Head to head
| Metric | RDY | NBIX |
|---|---|---|
| Price | $14.89 | $150.57 |
| Change today | ▲ 0.40% | ▼ 3.84% |
| Market cap | $12.41B | $15.24B |
| Return, 3 months | +21.8% | -1.6% |
| Return, year to date | +6.8% | +6.2% |
| Return, 1 year | +7.8% | +6.2% |
| P/E (TTM) | 41.4 | 22.3 |
| P/B | 3.0 | 3.9 |
| P/E percentile vs own 5y | 99th | 8th |
| Dividend yield | 0.56% | – |
| Revenue growth (YoY, latest qtr) | -1.5% | +41.2% |
| Net profit growth (YoY) | -36.0% | -1.4% |
| Gross margin | 49.5% | 97.7% |
| Operating margin | 9.5% | 24.6% |
| Net margin | 8.5% | 19.0% |
| Return on equity | 7.5% | 20.4% |
| Analyst target vs. price | -3.3% | +37.7% |
| Analyst buy share | 67% | 84% |
| RSI (14) | 68 | 43 |
| 30-day volatility | 21.8% | 50.0% |
| Max drawdown, 1 year | -26.0% | -27.2% |
| Trend read | Strong uptrend | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- NBIX is the largest of the group by market value.
- RDY has returned the most over the past year.
- NBIX carries the lowest trailing P/E.
- NBIX is growing revenue fastest.
- NBIX keeps the most profit per dollar of sales.
- RDY has been the calmest stock over the last 30 days.